
Opinion|Videos|October 14, 2024
COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS
Author(s)Yoshiaki Nakamura, MD, PhD
Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study demonstrated statistically significant recurrence-free intervals across various postoperative and adjuvant chemotherapy time points, highlighting the prognostic value of serial, tissue-free ctDNA assays for real-time detection of MRD vs single postchemotherapy assessments.
Advertisement
Episodes in this series

1. Please summarize the statistically significant recurrence-free intervals across the postoperative, post-ACT, and paired pre- and post-ACT analyses in the COSMOS-CRC-01 study.
2. Please address the prognostic value of serial, tissue-free, epigenomic ctDNA assays in detecting MRD in real time vs a single postchemotherapy time point.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5






























